Legal Proceedings Report • Jul 7, 2015
Legal Proceedings Report
Open in ViewerOpens in native device viewer
Lyon (France), 06 July 2015–ERYTECH (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative 'tumor starvation' treatments for acute leukemia and other oncology indications with unmet medical need, announces today it liquidity contract's first half review untrusted to the investment company Bryan, Garnier & Co.
Under the liquidity contract untrusted to Bryan, Garnier & Co, concerning ERYTECH's shares, the liquidity account held the following assets on 30 June 2015:
It should be noted that during the contract implementation, the following assets have been brought to the liquidity account:
ERYTECH Gil Beyen Chairman and CEO Tel: +33 4 78 74 44 38 [email protected] NewCap Julien Perez / Emmanuel Huynh Investor relations Nicolas Merigeau Press relations Tel: +33 1 44 71 98 52 [email protected]
This document may contain forward-looking statements and estimates with respect to the financial situation, the results of operations, the strategy, the project and to the anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results, the financial condition, performance or achievements of ERYTECH, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org), also available on our website (www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. ERYTECH disclaims any obligation to update any such forward-looking statement. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by French law.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.